RISK FACTORS FOR SARS-COV-2 INFECTION AND PECULIARITIES OF VIRAL SHEDDING IN PATIENTS WITH SARCOIDOSIS


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Objective. To study risk factors for SARS- CoV-2 in patients with sarcoidosis (S) and the features of viral shedding in them during the development of COVID-19. Subjects and methods. Nineteen case histories of S patients who had fallen ill with COVID-19 were analyzed. The diagnosis of S was confirmed morphologically, whereas COVID-19 was confirmed mainly by positive PCR tests for SARS-CoV-2 RNA. Mediastinal, pulmonary-and-mediastinal, and pulmonary S were diagnosed in 11, 6, and 2 cases, respectively. Sixteen patients with S before COVID-19 had a stable clinical condition that required no medical support. In unstable S, 1 patient took azathioprine (100 mg/day) and two had metypred (8 mg/day). As a result of treatment, all the patients with S recovered from COVID-19. All the 19 patients underwent an epidemiological analysis that included an assessment of the likely sources of SARS-CoV-2. Results. The patients with S were found to have contacts for coronavirus: familial (n = 8), working (n = 6), nosocomial (n = 3), household (n = 1), and unidentified (n = 1) contacts. The mean duration of viral shedding was 10.6±2.8 days in the Spatients. Six patients with S had mild COVID-19; 13 had a moderate course with recovery. Conclusion. The main risk factors for SARS-CoV-2 infection in S are familial and working contacts: being in the same room with the source of infection and professional activities associated with numerous contacts with a large number of people. COVID-19 in Spatients was characterized by its mild and moderate clinical course. The mean duration of viral shedding in this case was 10.6±2.8 days.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Авторлар туралы

Vitaly Dobin

Academician I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia

Email: viladob@gmail.com
MD, Professor, Department of Infectious Diseases and Phthisiology Ryazan, Russia

Ilya Panin

Academician I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia

Email: iliavpanin@gmail.com
Cand. Med. Sci., Assistant Professor, Department of Cardiovascular, X-Ray Endovascular Surgery and Radiodiagnosis Ryazan, Russia

Vladimir Martynov

Academician I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia

Email: dr.martinov@mail.ru
MD, Head, Department of Infectious Diseases and Phthisiology Ryazan, Russia

Әдебиет тізімі

  1. Добин В.Л., Панин И.В. Саркоидоз и COVID-19. Туберкулез и болезни легких 2021; 99 (8): 7-12. doi.org/10.21292/2075-1230-2021-99-8-7-12
  2. Визель А.А., Визель И.Ю., Костинов М.Л., Амиров Н.Б. Саркоидоз. Новая инфекция COVID-19 и вопросы вакцинации. Вестник современной клинической медицины 2021; 14 (4): 48-57. DOI: 10.20969/ VKSM.2021.14(4).48-57
  3. Manansala M., Ascoli C., Alburquerque A.G., Perkins D., Mirsaedi M., Finn P., Sweiss N.J. Case Series: COVID-19 in African American Patients With Sarcoidosis. Front Med. (Lausanne) 2020; (7): 588527. doi: 10.3389/fmed.2020.588527. PMID: 33251236;PMCID: PMC767220
  4. Morgenthau A.S., Levin M.A., Freeman R., Reich D.L., Klang E. Moderate or Severe Impairment in Pulmonary Function is Associated with Mortality in Sarcoidois Patients Infected with SARS-CoV-2. Lung 2020; 198 (5): 771-5. doi: 10.1007/s00408-020-00392-9
  5. Baughman R.P., Buchanon M., Rottoli P. et al. Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire. Sarcoidosis Vasc Lung Dis. 2020; 37: e2020009. doi: 10.36141/svdld.v37i4.10726
  6. Sweiss N.J., Korsten P., Syed H.J., Syed Aamer, Culver D.A., Sosenko T. et al. When the game changes: guidance to adjust sarcoidosis management during the COVID-19 pandemic. Chest 2020; 158 (3). doi: 10.1016/j.chest.2020.04.033

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Bionika Media, 2022